Scarica l'app Stockscreener
59.76
4.45%
2.5515
Precedente Chiudi:
$57.21
Aprire:
$57.89
Volume 24 ore:
517.90K
Relative Volume:
0.73
Capitalizzazione di mercato:
$4.27B
Reddito:
$58.89M
Utile/perdita netta:
$-240.88M
Rapporto P/E:
-19.28
EPS:
-3.1
Flusso di cassa netto:
$-239.96M
1 W Prestazione:
+3.83%
1M Prestazione:
+27.17%
6M Prestazione:
+147.75%
1 anno Prestazione:
+32.73%
Intervallo 1D:
$56.58
$59.98
Intervallo di 1 settimana:
$55.99
$59.98
Portata 52W:
$19.45
$59.98
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Confronta KYMR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
59.68 | 4.09B | 58.89M | -240.88M | -239.96M | -3.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.13 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-30 | Ripresa | B. Riley Securities | Buy |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-05-20 | Ripresa | Stifel | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Market Perform |
| 2024-12-02 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-26 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Iniziato | Oppenheimer | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Kymera Therapeutics stock hits 52-week high at 59.03 USD - Investing.com India
What earnings revisions data tells us about Kymera Therapeutics Inc.2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
What’s the recovery path for long term holders of Kymera Therapeutics Inc.Weekly Market Outlook & Smart Investment Allocation Tips - newser.com
Is Kymera Therapeutics Inc. stock attractive for ETFsJuly 2025 Setups & Free Weekly Chart Analysis and Trade Guides - newser.com
Custom strategy builders for tracking Kymera Therapeutics Inc.2025 Market Trends & Risk Adjusted Swing Trade Ideas - newser.com
Will Kymera Therapeutics Inc. see short term momentumOptions Play & AI Powered Market Entry Strategies - newser.com
Kymera Therapeutics Inc Stock Analysis and ForecastSupport and Resistance Levels & Free Stock Market Mentorship Programs - earlytimes.in
Full technical analysis of Kymera Therapeutics Inc. stock2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Kymera Therapeutics Inc. stock chart pattern explainedFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Ranking Kymera Therapeutics Inc. among high performing stocks via toolsWeekly Market Report & Risk Controlled Swing Alerts - newser.com
Should you hold or exit Kymera Therapeutics Inc. nowJuly 2025 Institutional & Real-Time Stock Movement Alerts - newser.com
Top chart patterns to watch in Kymera Therapeutics Inc.Market Trend Review & Community Verified Watchlist Alerts - newser.com
Kymera Therapeutics Hits New 52-Week High of $59.00, Up 69% - Markets Mojo
Analyzing net buyer seller activity in Kymera Therapeutics Inc.Sell Signal & High Yield Stock Recommendations - newser.com
Will Kymera Therapeutics Inc. stock maintain momentum in 20252025 Market WrapUp & Safe Capital Allocation Plans - newser.com
Tools to monitor Kymera Therapeutics Inc. recovery probabilityMarket Growth Summary & Capital Protection Trading Alerts - newser.com
Keudell Morrison Wealth Management Invests $334,000 in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics stock hits 52-week high at $58.97 By Investing.com - Investing.com Nigeria
Kymera Therapeutics stock hits 52-week high at $58.97 - Investing.com
What analysts say about Kymera Therapeutics Inc stockGlobal Trade Effects & Low Risk Capital Growth Plans - earlytimes.in
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $59.95 - Defense World
Real time pattern detection on Kymera Therapeutics Inc. stockMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
Kymera Therapeutics (NASDAQ:KYMR) Given New $68.00 Price Target at Truist Financial - Defense World
Oppenheimer Maintains Kymera Therapeutics (KYMR) Outperform Recommendation - Nasdaq
Kymera Therapeutics Hits New 52-Week High of $58.93, Up 65.21% - Markets Mojo
Is Codere Online Luxembourg SA a good long term investmentVolume Weighted Average Price & Learn the Basics of Investing in 5 Days - earlytimes.in
Oppenheimer Raises Price Target for Kymera Therapeutics (KYMR) t - GuruFocus
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline - Nasdaq
Oppenheimer Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $63 - 富途牛牛
Kymera Therapeutics (NASDAQ:KYMR) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
Truist Securities raises Kymera Therapeutics stock price target to $68 on KT-621 potential - Investing.com Canada
Truist Securities Boosts KYMR Price Target by Over 28% | KYMR Stock News - GuruFocus
Truist Financial Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $68.00 - MarketBeat
Truist Raises Price Target on Kymera Therapeutics to $68 From $53, Keeps Buy Rating - MarketScreener
Truist Financial Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $68 - 富途牛牛
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Published on: 2025-09-30 02:20:06 - newser.com
Kymera Therapeutics Hits New 52-Week High of $56.81, Up 64% Year-to-Date - Markets Mojo
Kymera Therapeutics (KYMR): Revisiting Valuation After Recent Share Price Momentum - Yahoo Finance
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kymera Therapeutics Inc Azioni (KYMR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Jacobs Bruce N. | Chief Financial Officer |
Sep 17 '25 |
Sale |
50.00 |
79,220 |
3,961,380 |
227,409 |
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):